Background and Aims: Butyricicoccus is a butyrate-producing clostridial cluster IV genus whose numbers are reduced in the stool of ulcerative colitis [UC] , and Butyricicoccus 16S rRNA expression was analysed in a collection of colonic biopsies of healthy controls and UC patients with active disease. The effect of butyrate and B. pullicaecorum conditioned medium on TJ gene expression was investigated in TNFα-stimulated Caco-2 monolayers and inflamed mucosal biopsies of UC patients. Results: TJP1 expression was significantly decreased in inflamed UC mucosa, whereas CLDN1 mRNA levels were increased. OCLN did not differ significantly between the groups. Mucosaassociated Butyricicoccus 16S rRNA transcripts were reduced in active UC patients compared with healthy controls. Interestingly, Butyricicoccus activity negatively correlated with CLDN1 expression. Butyrate reversed the inflammation-induced increase of CLDN1 protein levels, and stimulation of inflamed UC biopsies with B. pullicaecorum conditioned medium normalized CLDN1 mRNA levels. Conclusions: Butyricicoccus is a mucosa-associated bacterial genus under-represented in colonic mucosa of patients with active UC, whose activity inversely correlates with CLDN1 expression. Butyrate and B. pullicaecorum conditioned medium reduce CLDN1 expression, supporting its use as a pharmabiotic preserving epithelial TJ integrity.
Introduction
In the healthy gut, a symbiotic relationship exists between the host and commensal bacteria, which is of paramount importance to our general well-being. Commensals are crucial to the maintenance of immunological gut homeostasis. During adult life, the composition of the intestinal microbiota is fairly stable but may fluctuate due to infections or oral antibiotic treatment. This fluctuation generally entails a decrease in both bacterial abundance and diversity─a condition termed dysbiosis. 1 Several chronic diseases, including inflammatory bowel disease [IBD] , are associated with intestinal dysbiosis. IBD, comprising Crohn's disease [CD] and ulcerative colitis [UC] , is characterized by a chronic, relapsing inflammation of the gastrointestinal tract. The aetiology of IBD is unknown but inflammation most likely results from an abnormal mucosal immune response to antigens derived from the commensal microbiota in a genetically susceptible host. One of the most important microbial communities affected by intestinal inflammation are specific butyrate-producing members of the Firmicutes phylum like the Lachnospiraceae subgroup [which comprises Clostridium XIVa and IV groups within the order Clostridiales] which are under-represented in the mucosal microbiota of patients with IBD compared with healthy subjects. 2 Butyrate is a short-chain fatty acid produced during fermentation of dietary fibre in the colon. Besides being the main energy source for colonocytes, butyrate is also responsible for the maintenance of colonic homeostasis by modulating a wide variety of cellular functions including proliferation, differentiation, apoptosis, and the control of intestinal epithelial permeability. 3, 4 Butyrate is a potent anti-inflammatory mediator given its role in promoting epithelial barrier function, 5 its inhibitory effect on cytokine expression, 6 and its ability to induce differentiation of colonic regulatory T-cells. 7 Most of the butyrate-producing bacteria cultured so far belong to the clostridial clusters XIVa and IV that include Roseburia 8 and Faecalibacterium 9 species, respectively, two abundant colonizers of the human gut. A decrease in both Roseburia hominis and Faecalibacterium prausnitzii has been documented in stools of UC patients, with both species showing an inverse correlation with disease activity. 10 Consequently, there is increasing interest in using butyrate to restore homeostasis in IBD. However, its routine clinical application has been impeded by practical issues. When administered orally, butyrate might not reach the colon in sufficient amounts due to its rapid gastric and duodenal absorption. Besides, butyrate has a very unpleasant taste and smell. Rectal butyrate enemas have proven to be effective in treating distal UC 11, 12 but are cumbersome for the patient and exposure of the colonic mucosa to the butyrate is brief and discontinuous. The administration of naturally occurring butyrate-producing bacteria that would continuously secrete butyrate into the colonic lumen is an alternative strategy to locally increase butyrate concentrations. One of these high-level butyrateproducing bacteria is Butyricicoccus pullicaecorum [B. pullicaecorum], an anaerobic Gram-positive clostridial cluster IV species, first isolated from the caecal content of a broiler chicken. 13 The average number of Butyricicoccus is decreased in stool samples of IBD patients, and a specific B. pullicaecorum strain is able to reduce intestinal inflammation in a rat colitis model. Furthermore, its conditioned medium prevents cytokine-induced increase in epithelial permeability in vitro.
14 A dysfunctional epithelial barrier is one of the key characteristics of IBD. 15 This barrier consists of a single layer of epithelial cells linked together by tight junctions [TJs] which seal off the intercellular space and regulate selective paracellular ionic solute transport. TJs are composed of four different intergral membrane proteins: occludin [OCLN], tricellulin, junctional adhesion molecules, and claudins, which are linked to the actin cytoskeleton through scaffolding proteins like tight junction protein 1 [TJP1]. 16 In IBD, expression of most claudins─like other tight junction proteins─is reduced. 17 Remarkably, claudin-1 [CLDN1] protein levels are increased in areas of active inflammation. 18 Given the reduction of Butyricicoccus numbers in IBD and the ability of its conditioned medium to prevent cytokine-induced epithelial dysfunction, B. pullicaecorum bacteria therefore seem conceptually attractive as pharmabiotics to reduce intestinal inflammation or to prevent disease relapse in IBD patients. However, it is currently unknown how Butyricicoccus could affect barrier integrity in human IBD. Therefore, the purpose of this study was to detect and quantify Butyricicoccus in human colonic mucosa and to further investigate the host response to butyrate and conditioned medium of B. pullicaecorum in terms of epithelial barrier function. 19 but without clarified rumen fluid. The bacterial cells were collected by centrifugation [10 min, 5000 g, 37°C] and discarded. The resulting supernatant was sterile-filtered [0.22 µml] and the concentration of short-chain fatty acids [acetate, propionate, butyrate, isobutyrate, valerate, isovalerate, caproate, and isocaproate] was determined using a gas chromatograph as described previously. 20 Only butyrate was detected in supernatant of B. pullicaecorum T at a concentration of 4 mM.
Materials and Methods

Ethics statement
Stimulation of colonic mucosal biopsies with B. pullicaecorum conditioned medium
Colonic biopsies from patients with active UC [N = 25] were obtained as described above and harvested in RPMI 1640 medium supplemented with 10% fetal bovine serum [FBS], 10.000 units/ml penicillin, 10.000 µg/ml streptomycin, and 200 µg/ml gentamycin [all Life Technologies, Ghent, Belgium]. Patient characteristics are provided in Table 1 . Biopsies were cultured for 24 h with B. pullicaecorum conditioned medium diluted to contain 2 mM of butyrate or M2GSC anaerobic medium as control. Biopsies were recovered in RNAlater and stored at -80°C. 
Cell culture and induction of barrier dysfunction in vitro
RNA extraction
Total RNA from Caco-2, human mucosal biopsies and mouse terminal ileum tissue samples was extracted using the Qiagen RNeasy YWHAZ and HMBS for all other human biopsy cDNA and to HMBS and GAPDH for mouse terminal ileum tissue samples. To enable normalization to biopsy size, the number of cDNA copies corresponding to the Butyricicoccus 16S rRNA gene were normalized to the expression of human GAPDH, HMBS and YWHAZ as described previously. 21 The PCR efficiency of each primer pair was calculated using a standard curve of reference cDNA. Amplification efficiency was determined using the formula 10 -1/slope . Sequences of the primer sets are listed in Table 2 . 
Statistical analysis
Results
Tight junction gene expression is deregulated during intestinal inflammation
In order to link the presence of Butyricicoccus with barrier integrity in vivo, mRNA expression levels of three major TJ genes─CLDN1, TJP1 and OCLN─were measured in a collection of colonic mucosal biopsies from healthy controls [N = 36] and patients with active UC [N = 37] using qRT-PCR. Expression of TJP1 was significantly decreased [p < 0.001, Figure 1A ] in UC biopsies, whereas CLDN1 expression was significantly increased [p < 0.0001, Figure 1B] . Expression of OCLN did not differ significantly between active UC patients and healthy controls [p = 0.091, Figure 1C ]. In remission, no significant differences were observed [ Figure 1A -C]. The inflammation-associated upregulation of CLDN1 observed in active UC seems counterintuitive; however, increased CLDN1 levels have been reported in experimental models for colitis. 22 Also, inflammation of the ileum in TNF ΔARE/WT mice 23 exhibits an increased expression of Cldn1 [p = 0.0002, Figure 1D ].
Butyricicoccus activity is decreased in mucosal samples of patients with active UC
Next, we used this biopsy cohort to determine whether Butyricicoccus bacteria were present using genus-specific 16S rRNA primers. Butyricicoccus 16S rRNA levels could be measured adequately, ranging from 0 to 100.000 copies. Functionally active Butyricicoccus bacteria were detectable in all healthy control samples but below detection in eight out of 37 active UC samples [Fisher's exact test p = 0.0052]. In UC samples with detectable 16S rRNA transcripts, the absolute numbers were reduced compared with those of healthy controls [p = 0.046, Figure 2A] . Interestingly, the amount of Butyricicoccus inversely correlated with CLDN1 mRNA levels [Pearson R = -0.239, p = 0.024, Figure 2B ]. 
Butyrate counteracts TNFα-induced barrier disruption and TJ deregulation
Next, we questioned whether the in vitro model for barrier disruption using TNFα-stimulated Caco-2 monolayers mimics the deregulated TJ gene expression observed in UC biopsies. A significant drop in TEER was observed [p < 0.0001, Figure 3A ] 48 h following the addition of TNFα, which coincided with increased IL-8 production [p = 0.0043, Figure 3B ] and a significant reduction of TJP1 and OCLN mRNA levels [p = 0.0065 and 0.0014, respectively, Figure 3C -D], while CLDN1 mRNA [p = 0.012, Figure 3E ] and CLDN1 protein expression [ Figure   3F ] were increased. In addition, CLDN1, which localizes to the plasma membrane in functionally intact Caco-2 monolayers, internalized following TNFα stimulation [ Figure 3G ] Figure  3A -D]. Although the TNFα-induced increase in mRNA expression of CLDN1 was not influenced by butyrate [ Figure 3E ], total protein levels of CLDN1 [ Figure 3F ] were markedly decreased. However, cytoplasmic expression of CLDN1 was still observed [ Figure 3G] . 3.4. B. pullicaecorum conditioned medium reduces CLDN1 expression in mucosa of patients with active UC Finally, to investigate whether B. pullicaecorum affects TJ expression ex vivo, mucosal biopsies of UC patients with active disease [N = 25] were stimulated with B. pullicaecorum conditioned medium diluted to contain 2 mM of butyrate or an equal dilution of the growth medium control. After 24 h, a decrease in CLDN1 mRNA levels compared with medium control [p = 0.001, Figure 4A ] was observed whereas TJP1 and OCLN expression were not significantly affected by the conditioned medium [ Figure 4B , C].
Discussion
Intestinal epithelial TJ integrity is compromised in IBD. The observed abnormalities include reduced strand numbers, strand discontinuities, and reduced depth of the TJ complex. Changes in expression and localization of specific TJ molecules have also been described. 24, 25 In our collection of colonic mucosal biopsies, we also observed a severely deregulated expression of two major TJ genes─TJP1 and CLDN1─in samples of patients with active UC compared with healthy controls; TJP1 is under-represented in inflamed tissue, whereas CLDN1 is highly upregulated. A similar increase in Cldn1 was observed in a model for Crohn's-like ileitis due to constitutive overexpression of TNFα, a key pro-inflammatory cytokine in IBD. Likewise compromised TJ integrity, mimicked in vitro by stimulating differentiated Caco-2 monolayers with TNFα, leads to loss of TJP1 and OCLN and an increase in CLDN1. In addition, CLDN1, which is localized solely at the plasma membrane in functionally intact Caco-2 monolayers, internalizes following TNFα-stimulation. Under normal physiological conditions, CLDN1 is a key pore-sealing TJ protein crucial to epithelial barrier integrity; its genetic deletion results in rapid postnatal death due to severe epidermal permeability defects. 26 Also, baseline CLDN1 overexpression in vitro results in increased barrier tightness, whereas its concomitant knockdown decreases it. 5 Under inflammatory conditions however, the role of CLDN1 is much less straightforward. In agreement with upregulated CLDN1 mRNA levels in our cohort, increased CLDN1 protein levels have been documented in IBD and in acute dextran sodium sulphate-induced colitis. 27, 22 Also, its intestinal epithelial overexpression renders mice more susceptible to colitis and impairs their recovery. 28 Interestingly, in vitro pro-inflammatory cytokineinduced upregulation of CLDN1 coincides with a redistribution of the protein away from the TJs 29, 30 and a concomitant increase in intestinal permeability. So, it appears that elevating CLDN1 expression under baseline conditions increases epithelial barrier integrity, whereas under inflammatory conditions its internalization causes a weakening of the intestinal barrier despite an increase in overall expression.
Next, we found that this aberrant CLDN1 expression in colonic mucosa of active UC patients negatively correlates with reduced Butyricicoccus activity. The detection of the genus Butyricicoccus in mucosal tissue is in agreement with a study published by Nava and Stappenbeck who identified Butyricicoccus as an autochthonous microbe predominantly colonizing the mucosa-associated surface of the colon. 31 This close proximity of Butyricicoccus bacteria to the apical surface of the colonic epithelium facilitates host access to its metabolites, like butyrate, which are essential to cellular homeostasis. Since butyrate is known to promote intestinal epithelial barrier function, we analysed its effect on TNFα-induced deregulation of TJ gene expression in vitro. Butyrate completely prevented loss of TEER in TNFα-stimulated Caco-2 monolayers while increasing TJP1 and OCLN expression. Neither increased CLDN1 mRNA levels nor CLDN1 internalization was reduced by butyrate; however, a drop in total CLDN1 protein levels was observed. Finally, ex vivo stimulation of inflamed UC biopsies showed that the observed in vitro effects of butyrate could be mimicked by B. pullicaecorum conditioned medium, i.e. a marked reduction in CLDN1 levels.
In conclusion, this study demonstrates that the functions of CLDN1 are not restricted to its traditional role of maintaining intestinal barrier function and that its elevation during mucosal inflammation is detrimental to both epithelial integrity and further downstream pathways responsible for colonic homeostasis. Given the effect of both butyrate and B. pullicaecorum conditioned medium on CLDN1 expression, these results further substantiate the use of Butyricicoccus as a pharmabiotic in order to preserve epithelial TJ integrity. 
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